{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By THE ASSOCIATED PRESS", "person": [], "organization": "THE ASSOCIATED PRESS"}, "abstract": "Food and Drug Administration approves Celltrion and Pfizer's quasi generic drug Inflectra, less expensive version of Remicade, Johnson & Johnson's costly biotech drug for treatment of inflammatory diseases.", "type_of_material": "News", "word_count": "165", "lead_paragraph": "Federal officials have approved a cheaper version of Johnson &amp; Johnson\u2019s blockbuster drug Remicade, a biotech medicine for inflammatory diseases.", "pub_date": "2016-04-06T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "F.D.A. Clears Cheaper Version of Johnson &amp; Johnson Biologic", "content_kicker": "Business Briefing", "print_headline": "F.D.A. Clears Cheaper Version of Johnson &amp; Johnson Biologic", "kicker": "Business Briefing"}, "snippet": "Federal officials have approved a cheaper version of Johnson &amp; Johnson\u2019s blockbuster drug Remicade, a biotech medicine for inflammatory diseases.", "multimedia": [], "web_url": "http://www.nytimes.com/2016/04/06/business/fda-clears-cheaper-version-of-johnson-johnson-biologic.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Pfizer Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Celltrion Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Johnson & Johnson", "name": "organizations"}, {"rank": "5", "is_major": "Y", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Biotechnology and Bioengineering", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Generic Brands and Products", "name": "subject"}, {"rank": "8", "is_major": "N", "value": "Remicade (Drug)", "name": "subject"}], "blog": [], "_id": "57045b2c38f0d848959bee30", "source": "The New York Times"}